Torthaí cuardaigh údar :: UTM Library Massive Scholar Tracking

1

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate de réir Coates, LC, Deodhar, A

Foilsithe / Cruthaithe 2023

Journal article

2

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... de réir Coates, LC, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

Foilsithe / Cruthaithe 2022

Journal article

3

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... de réir Coates, L, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

Foilsithe / Cruthaithe 2022

Journal article

4

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial de réir Helliwell, PS, Mease, PJ, Kavanaugh, A, Coates, LC, Ogdie, A, Deodhar, A, Strand, V, Kricorian, G, Liu, L, Collier, D, Gladman, DD

Foilsithe / Cruthaithe 2022

Journal article

5

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from t... de réir Orbai, AM, Coates, LC, Deodhar, A, Helliwell, P, Ritchlin, CT, Kollmeier, A, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Foilsithe / Cruthaithe 2021

Conference item

6

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial de réir Strand, V, Gossec, L, Coates, LC, Ogdie, A, Choi, J, Becker, B, Zhuo, J, Lehman, T, Nowak, M, Elegbe, A, Mease, PJ, Deodhar, A

Foilsithe / Cruthaithe 2024

Journal article

7

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies de réir Baraliakos, X, Ranza, R, Östör, A, Ciccia, F, Coates, LC, Rednic, S, Walsh, JA, Douglas, K, Gao, T, Kato, K, Song, I-H, Ganz, F, Deodhar, A

Foilsithe / Cruthaithe 2023

Journal article

8

Meaningful improvement in general health outcomes with Guselkumab treatment for psoriatic arthritis: Patient-Reported Outcomes Measurement Information System-29 results from a phas... de réir Orbai, A-M, Coates, LC, Deodhar, A, Helliwell, PS, Ritchlin, CT, Leibowitz, E, Kollmeier, AP, Hsia, EC, Xu, XL, Sheng, S, Jiang, Y, Liu, Y, Han, C

Foilsithe / Cruthaithe 2022

Journal article

9

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis de réir Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Foilsithe / Cruthaithe 2024

Journal article

10

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis de réir Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Foilsithe / Cruthaithe 2024

Journal article

11

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis de réir Singh, JA, Guyatt, G, Ogdie, A, Gladman, DD, Deal, C, Deodhar, A, Dubreuil, M, Dunham, J, Husni, ME, Kenny, S, Kwan-Morley, J, Lin, J, Marchetta, P, Mease, PJ, Merola, JF, Miner, J, Ritchlin, CT, Siaton, B, Smith, BJ, Voorhees, AS, Jonsson, AH, Shah, AA, Sullivan, N, Turgunbaev, M, Coates, LC, Gottlieb, A, Magrey, M, Nowell, WB, Orbai, AM, Reddy, SM, Scher, JU, Siegel, E, Siegel, M, Walsh, JA, Turner, AS, Reston, J

Foilsithe / Cruthaithe 2018

Journal article

12

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis de réir Singh, J, Guyatt, G, Ogdie, A, Gladman, D, Deal, C, Deodhar, A, Dubreuil, M, Dunham, J, Husni, M, Kenny, S, Kwan-Morley, J, Lin, J, Marchetta, P, Mease, P, Merola, J, Miner, J, Ritchlin, C, Siaton, B, Smith, B, Van Voorhees, A, Jonsson, A, Shah, A, Sullivan, N, Turgunbaev, M, Coates, L, Gottlieb, A, Magrey, M, Nowell, W, Orbai, A, Reddy, S, Scher, J, Siegel, E, Siegel, M, Walsh, J, Turner, A, Reston, J

Foilsithe / Cruthaithe 2018

Journal article

13

Proceedings of the GRAPPA 2022 executive retreat de réir Ng, B, Jadon, D, Adebajo, A, Ayan, G, Callis Duffin, K, Chandran, V, Coates, LC, D’Agostino, MA, de Vlam, K, Deodhar, A, Eder, L, Garg, A, Gladman, DD, Goel, N, Gottlieb, A, Husni, ME, Katz, A, Kavanaugh, A, Lubrano, E, Mease, P, Merola, J, Nash, P, Ogdie, A, Pennington, S, Perez-Chada, LM, Proft, F, Rosen, CF, Savage, L, Goldenstein-Schainberg, C, Siebert, S, Soriano, E, Steinkoenig, I, Tillett, W, Armstrong, A, FitzGerald, O

Foilsithe / Cruthaithe 2023

Journal article

14

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis de réir Singh, J, Guyatt, G, Ogdie, A, Gladman, D, Deal, C, Deodhar, A, Dubreuil, M, Dunham, J, Husni, M, Kenny, S, Kwan-Morley, J, Lin, J, Marchetta, P, Mease, P, Merola, J, Miner, J, Ritchlin, C, Siaton, B, Smith, B, Van Voorhees, A, Jonsson, A, Shah, A, Sullivan, N, Turgunbaev, M, Coates, L, Gottlieb, A, Magrey, M, Nowell, W, Orbai, A, Reddy, S, Scher, J, Siegel, E, Siegel, M, Walsh, J, Turner, A, Reston, J

Foilsithe / Cruthaithe 2018

Journal article

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate de réir Coates, LC, Deodhar, A

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... de réir Coates, LC, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-... de réir Coates, L, Mease, P, Kronbergs, A, Helt, C, Sandoval, D, Park, SY, Combe, B, Nash, P, Deodhar, A

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial de réir Helliwell, PS, Mease, PJ, Kavanaugh, A, Coates, LC, Ogdie, A, Deodhar, A, Strand, V, Kricorian, G, Liu, L, Collier, D, Gladman, DD

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial de réir Strand, V, Gossec, L, Coates, LC, Ogdie, A, Choi, J, Becker, B, Zhuo, J, Lehman, T, Nowak, M, Elegbe, A, Mease, PJ, Deodhar, A

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies de réir Baraliakos, X, Ranza, R, Östör, A, Ciccia, F, Coates, LC, Rednic, S, Walsh, JA, Douglas, K, Gao, T, Kato, K, Song, I-H, Ganz, F, Deodhar, A

Uirlisí cuardaigh: